News

Accorto Regulatory Solutions Launches Dedicated Quality & Compliance Division

Accorto Regulatory Solutions, LLC (Accorto), a U.S.-based regulatory advisory firm, announced the launch of its dedicated Quality & Compliance Division, expanding the firm’s ability to deliver integrated regulatory and compliance support to organizations involved in the development of FDA-regulated products.

The new division formalizes and expands Accorto’s compliance and GxP services in response to growing client demand for coordinated quality and regulatory support. The dedicated structure enables Accorto to deliver focused compliance expertise while scaling services to meet evolving client needs, including GxP compliance, quality system development, inspection readiness, and ongoing compliance activities. These services complement the firm’s established regulatory strategy and FDA application development offerings, enabling more seamless engagement across regulatory and operational functions.

“As our clients’ needs have evolved, so have we,” said Tom Beaudet, Chief Executive Officer of Accorto Regulatory Solutions. “Formalizing our compliance services into a dedicated division allows us to take a more strategic, scalable approach while continuing to deliver the hands-on support our clients rely on. This launch reflects our long-term vision of being a truly full-service regulatory and compliance partner.”

The Quality & Compliance Division will be led by Kristina Haysmer, who has been named Vice President of Compliance Consulting. A foundational member of Accorto, Kristina has played a key role in shaping the firm’s growth and service offerings since its inception. In her new role, she will guide the strategic development of the division, ensuring alignment with client needs and Accorto’s long-term objectives.

“With the launch of this division, we are reinforcing our commitment to meeting clients where they are and supporting them at every stage,” said Kristina. “Our goal is to deliver seamless, integrated solutions that reduce complexity and help organizations operate with confidence in highly regulated markets.”

Read more.

Recent News

10/23/2026

PAK BioSolutions and iBET Advance Integrated Continuous AAV8 Purification

PAK BioSolutions today announced the publication of a peer-reviewed study on integrated, continuous purification of adeno-associated virus serotype 8 (AAV8) using the PAK PD™ Process Development Scale Continuous Purification System. Conducted in collaboration with iBET – Instituto de Biologia Experimental e Tecnológica, the study, “Streamlining AAV8 Purification with Cyclic Integrated Capture–Polishing Chromatography,” was published in …

10/22/2026

Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020

Eli Lilly and Company (NYSE: LLY) broke ground today on a new $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County, one of 10 new U.S. manufacturing sites announced since 2020 and one of five among them that will produce active pharmaceutical ingredients (API). As part of the company’s more than $50 …

10/21/2026

United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the opening of its third Designated Pathogen-Free (DPF) facility, The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility, in Houston, Texas. United Therapeutics opened its first DPF facility in Christiansburg, Va. in 2024 to produce xenografts for ongoing clinical trials. …